​

Funding Round

Series B - Angitia Biopharmaceuticals

Series B - Angitia Biopharmaceuticals

Investment Firm

Overview

Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.

Announced Date

Oct 19, 2023

Funding Type

Series B

Highlights

Location

Asia

Social

Investor Lead

Morningside Group

Morningside Group

Morningside Group is a early_stage_venture and late_stage_venture and private_equity and seed firm.

Participant Investors

6

Investor Name
Participant InvestorOriza Holdings
Participant InvestorYonghua Capital
Participant InvestorLegend Capital
Participant InvestorOrbiMed
Participant InvestorMorningside Group

Round Details and Background

Angitia Biopharmaceuticals raised $46000000 on 2023-10-19 in Series B

Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 19, 2023
Series B - Angitia Biopharmaceuticals
7-46.0M
Oct 01, 2021
Series B - Angitia Biopharmaceuticals
1-70.0M
Sep 04, 2020
Series A - Angitia Biopharmaceuticals
6-undefined
Feb 28, 2024
Series B - Angitia Biopharmaceuticals
1-40.0M

Recent Activity

There is no recent news or activity for this profile.